Examining the Impact of U.S. Drug Pricing Pressure on Canada
ALS Action Canada Advocacy Committee member Dr. Andrew Darke co-authored a Financial Post commentary examining how U.S. drug pricing pressure could affect Canada’s pharmaceutical landscape, investment and access to innovative treatments, including therapies for people living with ALS.